Summit Securities Group LLC Acquires Shares of 41,680 Sanofi (NASDAQ:SNY)

Summit Securities Group LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,680 shares of the company’s stock, valued at approximately $2,312,000. Sanofi accounts for approximately 0.4% of Summit Securities Group LLC’s investment portfolio, making the stock its 18th largest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cardinal Capital Management boosted its holdings in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock worth $3,827,000 after acquiring an additional 199 shares during the period. Gradient Investments LLC boosted its holdings in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock worth $542,000 after acquiring an additional 200 shares during the period. Perigon Wealth Management LLC boosted its holdings in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock worth $367,000 after acquiring an additional 201 shares during the period. Beacon Financial Group boosted its holdings in shares of Sanofi by 1.6% in the first quarter. Beacon Financial Group now owns 14,398 shares of the company’s stock worth $799,000 after acquiring an additional 222 shares during the period. Finally, AdvisorNet Financial Inc raised its position in shares of Sanofi by 16.4% in the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after buying an additional 227 shares in the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Up 1.5%

Shares of SNY stock opened at $49.77 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $48.57 and a two-hundred day moving average price of $51.83. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The firm has a market cap of $122.21 billion, a P/E ratio of 11.96, a price-to-earnings-growth ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%. The firm had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period last year, the firm earned $1.73 EPS. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. Equities analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of recent analyst reports. Guggenheim reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley set a $56.00 price objective on Sanofi in a research report on Monday, June 2nd. Finally, Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.